Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Cater · SciRah

Researcher profile · Semantic Scholar

N. Cater

Share profile

N. Cater — researcher profile on SciRah

h-index: 22
Works: 71
Citations: 2,530

Most-cited papers

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
J. Kastelein, W. A. van der Steeg, I. Holme, M. Gaffney +10 more
2008Circulation508 citations Open access
Semantic Scholar
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference.
P. Kirchhof, G. Lip, I. V. van Gelder, J. Bax +52 more
2012Europace251 citations Open access
Semantic Scholar
Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.
S. Blair, D. Capuzzi, S. Gottlieb, Tu Nguyen +2 more
2000American Journal of Cardiology249 citations
Semantic Scholar
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
M. Ezekowitz, C. Pollack, J. Halperin, R. England +7 more
2018European Heart Journal174 citations Open access
Semantic Scholar
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
G. Vega, P. Ma, N. Cater, N. Filipchuk +3 more
2003American Journal of Cardiology164 citations
Semantic Scholar
Comparison of the effects of medium-chain triacylglycerols, palm oil, and high oleic acid sunflower oil on plasma triacylglycerol fatty acids and lipid and lipoprotein concentrations in humans.
N. Cater, H. J. Heller, M. Denke
1997American Journal of Clinical Nutrition150 citations Open access
Semantic Scholar
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease
F. Cosentino, C. Cannon, D. Cherney, Urszula Masiukiewicz +10 more
2020Circulation136 citations Open access
Semantic Scholar
Behenic acid is a cholesterol-raising saturated fatty acid in humans.
N. Cater, M. Denke
2001American Journal of Clinical Nutrition118 citations Open access
Semantic Scholar
Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.
G. Vega, N. Cater, S. Meguro, S. Grundy
2005American Journal of Cardiology79 citations
Semantic Scholar
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
M. Tikkanen, M. Szarek, R. Fayyad, I. Holme +7 more
2009Journal of the American College of Cardiology76 citations Open access
Semantic Scholar
Responsiveness of plasma lipids and lipoproteins to plant stanol esters.
N. Cater, A. García-García, G. Vega, S. Grundy
2005American Journal of Cardiology69 citations
Semantic Scholar
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
M. Tikkanen, I. Holme, N. Cater, M. Szarek +6 more
2009American Journal of Cardiology63 citations
Semantic Scholar
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)
I. Holme, N. Cater, O. Faergeman, J. Kastelein +6 more
2008Annals medicus59 citations Open access
Semantic Scholar
Intensive early and sustained lowering of non–high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry
J. Schubert, M. Leósdóttir, B. Lindahl, J. Westerbergh +6 more
2024European Heart Journal51 citations Open access
Semantic Scholar
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table.
F. Mach, F. Visseren, N. Cater, Néjoua Salhi +12 more
2024Journal of Clinical Lipidology50 citations Open access
Semantic Scholar
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).
T. Pedersen, N. Cater, O. Faergeman, J. Kastelein +6 more
2010American Journal of Cardiology43 citations
Semantic Scholar
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
B. Wojeck, S. Inzucchi, I. Neeland, J. Mancuso +6 more
2022Sleep and Breathing37 citations Open access
Semantic Scholar
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome
G. Vega, N. Cater, Dariusch R. Hadizadeh, S. Meguro +1 more
2003Clinical pharmacology and therapy37 citations
Semantic Scholar
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.
M. Ezekowitz, C. Pollack, P. Sanders, J. Halperin +6 more
2016American Heart Journal36 citations Open access
Semantic Scholar
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes
Matthew W. Segar, A. Kolkailah, R. Frederich, A. Pong +11 more
2022Diabetes, obesity and metabolism31 citations Open access
Semantic Scholar
Plant stanol ester: review of cholesterol-lowering efficacy and implications for coronary heart disease risk reduction.
N. Cater
2000Preventive Cardiology28 citations
Semantic Scholar
Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis
A. Mcneill, G. Davies, E. Kruger, S. Kowal +5 more
2019Diabetes Therapy25 citations Open access
Semantic Scholar
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study
I. Holme, M. Szarek, N. Cater, O. Faergeman +6 more
2009European Journal of Cardiovascular Prevention & Rehabilitation20 citations
Semantic Scholar
Historical and scientific basis for the development of plant stanol ester foods as cholesterol-lowering agents
N. Cater
199915 citations
Semantic Scholar
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
K. Corbin, S. Dagogo-Jack, C. Cannon, D. Cherney +7 more
2022Diabetes, obesity and metabolism11 citations Open access
Semantic Scholar
Serum low-density lipoprotein cholesterol response to modification of saturated fat intake: recent insights.
N. Cater, Abhimanyu Garg
1997Current Opinion in Lipidology11 citations
Semantic Scholar
Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV
V. Sridhar, F. Cosentino, Samuel Dagogo-Jack, Darren K. McGuire +6 more
2024Diabetes, obesity and metabolism9 citations Open access
Semantic Scholar
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus
Jie Liu, Shrita M. Patel, N. Cater, Larry Wu +6 more
2019Diabetes, obesity and metabolism8 citations Open access
Semantic Scholar
The effect of dietary intervention on serum lipid levels in type 2 diabetes mellitus
N. Cater, A. Garg
2002Current Diabetes Reports4 citations
Semantic Scholar
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease
Joseph M Kim, D. Bhatt, S. Dagogo-Jack, D. Cherney +8 more
2023Diabetes, obesity and metabolism3 citations Open access
Semantic Scholar
Abstract 3357: Superiority of ApoB/ApoA1 Ratio for Predicting Cardiovascular Risk in Pooled Analyses of the Incremental Decrease in Endpoints through Aggressive Lipid-Lowering (IDEAL) and Treating to New Targets (TNT) Trials
J. Kastelein, I. Holme, P. Barter, A. Olsson +6 more
20063 citations
Semantic Scholar
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial
D. Cherney, R. Frederich, R. Pratley, F. Cosentino +7 more
2025Kidney Diseases2 citations
Semantic Scholar
Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial
Francesco Cosentino, Samuel Dagogo-Jack, R. Frederich, Christopher P. Cannon +7 more
2024Diabetes, obesity and metabolism2 citations Open access
Semantic Scholar
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial
Ambarish Pandey, A. Kolkailah, Francesco Cosentino, C. Cannon +8 more
2023European Heart Journal2 citations Open access
Semantic Scholar
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
F. Cosentino, C. Cannon, R. Frederich, D. Cherney +7 more
2022Circulation2 citations Open access
Semantic Scholar
481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV
Joseph M Kim, D. Bhatt, S. Dagogo-Jack, D. Cherney +8 more
2022Diabetes2 citations
Semantic Scholar
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial
Ambarish Pandey, A. Kolkailah, Darren K. McGuire, R. Frederich +10 more
2025European Journal of Heart Failure1 citations Open access
Semantic Scholar
Estimating adult cancer cachexia prevalence and impact on survival in the US: Real-world data analysis.
E. Roeland, Jeffrey Crawford, R. Dunne, Ira Jacobs +4 more
2024Journal of Clinical Oncology1 citations
Semantic Scholar
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
L. Ji, Jie Liu, Zhi-Jin Xu, Zhiqi Wei +4 more
2023Diabetes Therapy1 citations Open access
Semantic Scholar
HEART FAILURE OUTCOMES CAPTURED BY ADVERSE EVENT REPORTING IN PARTICIPANTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: OBSERVATIONS FROM THE VERTIS CV TRIAL
A. Pandey, A. Kolkailah, D. McGuire, R. Frederich +10 more
2023Journal of the American College of Cardiology1 citations Open access
Semantic Scholar
Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV
D. Cherney, M. Segar, A. Pandey, C. Cannon +10 more
2021European Heart Journal1 citations Open access
Semantic Scholar
206: A Comparison of the Association of On-Treatment Lipid and Apolipoprotein Parameters to Cardiovascular Events in IDEAL and TNT
J. Kastelein, I. Holme, W. A. van der Steeg, P. Barter +6 more
20071 citations
Semantic Scholar
DIETARY FAT AND HEALTH. AUTHORS' REPLY
R. Wood, N. Cater, M. Denke
19971 citations
Semantic Scholar
Association of Ertugliflozin on Kidney Outcomes in People After and Without an Interval Cardiovascular Event: Observations From the VERTIS CV Trial.
Ayodele Odutayo, F. Cosentino, Richard E. Pratley, Christopher P. Cannon +6 more
2026American Journal of Kidney Diseases0 citations Open access
Semantic Scholar
EFFECT OF ERTUGLIFLOZIN ON KIDNEY OUTCOMES IN ADULTS WITH AND WITHOUT AN INTERVAL CARDIOVASCULAR EVENT - A SECONDARY ANALYSIS OF VERTIS CV
Ayodele Odutayo, F. Cosentino, Samuel Dagogo-Jack, R. Pratley +7 more
2025Journal of the American College of Cardiology0 citations Open access
Semantic Scholar
Effects of Ertugliflozin by Uric Acid Quintile: Observations from VERTIS CV
Vikas S. Sridhar, F. Cosentino, Samuel Dagogo-Jack, R. Pratley +5 more
2023Journal of the American Society of Nephrology0 citations
Semantic Scholar
IDF2022-0796 Sustained weight loss with ertugliflozin in patients with T2D and atherosclerotic cardiovascular disease in VERTIS CV
F. Cosentino, S. Dagogo-Jack, R. Frederich, C. Cannon +6 more
2023Diabetes Research and Clinical Practice0 citations
Semantic Scholar
Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial
A. Pandey, A. Kolkailah, F. Cosentino, C. Cannon +8 more
2022European Heart Journal0 citations Open access
Semantic Scholar
EFFICACY OF ERTUGLIFLOZIN ON HEART FAILURE HOSPITALIZATION AND HF DEATH ACROSS THE WATCH-DM RISK SCORE: A SECONDARY ANALYSIS OF THE VERTIS CV TRIAL
Matthew W. Segar, D. McGuire, R. Frederich, D. Cherney +10 more
2022Journal of the American College of Cardiology0 citations Open access
Semantic Scholar
Abstract 9341: Hepatic Steatosis Index and Fibrosis-4 Scores in Patients With Type 2 Diabetes - Post Hoc Analyses from VERTIS CV
K. Corbin, Samuel Dagogo-Jack, Christopher P. Cannon, D. Cherney +8 more
2021Circulation0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Cherney×20
Invite
D. Cherney — researcher profile on SciRah
R. Frederich×20
Invite
R. Frederich — researcher profile on SciRah
R. Pratley×15
Invite
R. Pratley — researcher profile on SciRah
F. Cosentino×13
Invite
F. Cosentino — researcher profile on SciRah

×11

Invite

S. Dagogo-Jack — researcher profile on SciRah

Invite

J. Mancuso — researcher profile on SciRah

Invite

D. McGuire — researcher profile on SciRah

Invite

C. Cannon — researcher profile on SciRah

J. Kastelein×8

Invite

J. Kastelein — researcher profile on SciRah

Invite

I. Holme — researcher profile on SciRah

Invite

A. Olsson — researcher profile on SciRah

Invite

T. Pedersen — researcher profile on SciRah